MAVDA

The mission of the Metropolitan AntiViral Drug Accelerator (MAVDA) is to conduct innovative, multidisciplinary research to develop, optimize and test innovative small molecule antiviral drugs that target coronaviruses (such as SARS-CoV-2), and other viral families with high potential to cause a pandemic in the future. Our goal is to rapidly develop antiviral drugs that can be given orally in an outpatient setting... MAVDA is funded by a three-year, $65,141,731 million grant from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Disease (NIAID). MAVDA is one among the nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program funded by the NIAID, and involves world-class institutions in the New Jersey-New York metropolitan area, and beyond... MAVDA combines world-class virologists and academic drug development researchers from Rockefeller University, Columbia University and Memorial Sloan-Kettering Cancer Center..

Primary location: Nutley United States